Astellas Pharma is focusing on diversification, with its portfolio spanning cancer, vision loss and menopause treatments. Its Chief Medical Officer, Tadaaki Taniguci, said the company was also expanding its gene therapy output, using acquisitions and licensing to build capability, while in oncology, the firm’s lead drugs include treatments for prostate and bladder cancer. Astellas is also testing a small molecule for treating menopause symptoms.
North Korean Hackers Use Fake U.S. Companies to Spread Malware in Crypto Industry: Report
North Korean hackers reportedly set up shell companies in the US to penetrate the crypto sector and target developers via fake job offers, according to
